While they do carry higher-than-average risk, these microcaps also offer major upside potential for investors seeking startup-sized returns.
Kronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -6.98% and 89.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising...
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising...
/PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider...
/CNW/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of...
The consensus price target hints at a 311.9% upside potential for Kronos Bio, Inc. (KRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
Kronos Bio, Inc. (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute...
Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid...